File downloaded on 2026-11-29
Source URL: https://medicines.health.europa.eu/veterinary/en/600000023206

Equibactin vet. 250 mg/g + 50 mg/g, oral powder

Authorised

- Trimethoprim
- Sulfadiazine

Product identification

Medicine name:
Equibactin vet. 250 mg/g + 50 mg/g, oral powder

Active substance:
Trimethoprim

Sulfadiazine

Target species:
Horse

Route of administration:
Oral use

Product details

Active substance and strength:
Trimethoprim
50.00 milligram(s) / 1.00 gram(s)

Sulfadiazine

250.00 milligram(s) / 1.00 gram(s)

Pharmaceutical form:
Oral powder

Withdrawal period by route of administration:
Oral use:

- **Horse**
  - Meat and offal. 20 day

Not permitted for use in mares producing milk for human consumption.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01EW10

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Package description:
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish

Available only in Swedish
Available only in Swedish
Available only in Swedish
Available only in Swedish

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Dechra Regulatory B.V.

Marketing authorisation date:
6/04/2023

Manufacturing sites for batch release:
Lelypharma B.V.

Responsible authority:
National Organization For Medicines

Authorisation number:
35312/07-04-2023/K-0166002

Date of authorisation status change:
6/04/2023

Reference member state:
Sweden

Procedure number:
SE/V/0120/001

Concerned member states:
Austria Belgium Croatia Cyprus Estonia France Germany Greece Hungary

Iceland Ireland Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 9/02/2026
Updated on: 14/03/2026
Download

Package Leaflet

English (PDF)
Published on: 9/02/2026
Updated on: 14/03/2026
Download

Labelling